tradingkey.logo
tradingkey.logo

Gilead Sciences Inc

GILD
136.890USD
-1.220-0.88%
Fechamento 03/26, 16:00ETCotações atrasadas em 15 min
830.31BValor de mercado
20.01P/L TTM

Gilead Sciences Inc

136.890
-1.220-0.88%

Mais detalhes de Gilead Sciences Inc Empresa

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.

Informações de Gilead Sciences Inc

Código da empresaGILD
Nome da EmpresaGilead Sciences Inc
Data de listagemJan 22, 1992
CEOO'Day (Daniel P)
Número de funcionários17600
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 22
Endereço333 Lakeside Dr
CidadeFOSTER CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404-1147
Telefone16505743000
Sitehttps://www.gilead.com/
Código da empresaGILD
Data de listagemJan 22, 1992
CEOO'Day (Daniel P)

Executivos da empresa Gilead Sciences Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
104.55K
+0.38%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+5.82%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+12.90%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel P. O'Day
Mr. Daniel P. O'Day
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
104.55K
+0.38%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+5.82%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+12.90%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por EmpresaUSD
Nome
Receita
Proporção
Biktarvy
3.69B
47.46%
Descovy
698.00M
8.98%
Royalty Contract and other revenues
423.00M
5.44%
Genvoya
376.00M
4.84%
Trodelvy
357.00M
4.60%
Outro
2.23B
28.68%
Por RegiãoUSD
Nome
Receita
Proporção
United States
5.01B
64.45%
Europe
1.51B
19.47%
Other Locations
837.00M
10.77%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Biktarvy
3.69B
47.46%
Descovy
698.00M
8.98%
Royalty Contract and other revenues
423.00M
5.44%
Genvoya
376.00M
4.84%
Trodelvy
357.00M
4.60%
Outro
2.23B
28.68%

Distribuição de ações

Atualizado em: sex, 13 de fev
Atualizado em: sex, 13 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.71%
BlackRock Institutional Trust Company, N.A.
6.12%
State Street Investment Management (US)
4.85%
Fidelity Management & Research Company LLC
4.76%
Capital World Investors
3.45%
Outro
71.11%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.71%
BlackRock Institutional Trust Company, N.A.
6.12%
State Street Investment Management (US)
4.85%
Fidelity Management & Research Company LLC
4.76%
Capital World Investors
3.45%
Outro
71.11%
Tipos de investidores
Investidores
Proporção
Investment Advisor
55.87%
Investment Advisor/Hedge Fund
25.35%
Pension Fund
3.10%
Research Firm
2.96%
Bank and Trust
1.89%
Sovereign Wealth Fund
1.87%
Hedge Fund
1.48%
Insurance Company
0.15%
Individual Investor
0.09%
Outro
7.24%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
3534
1.15B
92.30%
-3.11M
2025Q3
3433
1.13B
91.16%
+23.58K
2025Q2
3388
1.12B
90.01%
-12.02M
2025Q1
3442
1.12B
90.14%
-10.49M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
118.39M
9.54%
-392.37K
-0.33%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
72.73M
5.86%
+1.93M
+2.72%
Sep 30, 2025
State Street Investment Management (US)
59.09M
4.76%
-98.86K
-0.17%
Sep 30, 2025
Fidelity Management & Research Company LLC
53.80M
4.34%
+39.02K
+0.07%
Sep 30, 2025
Capital World Investors
45.18M
3.64%
-1.12M
-2.43%
Sep 30, 2025
Geode Capital Management, L.L.C.
29.93M
2.41%
+721.32K
+2.47%
Sep 30, 2025
Invesco Capital Management (QQQ Trust)
27.84M
2.24%
+1.83M
+7.02%
Dec 31, 2025
Dodge & Cox
30.13M
2.43%
-685.19K
-2.22%
Sep 30, 2025
T. Rowe Price Associates, Inc.
24.42M
1.97%
+2.87M
+13.33%
Sep 30, 2025
Capital Research Global Investors
30.01M
2.42%
-1.08M
-3.48%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sex, 5 de dez
Atualizado em: sex, 5 de dez
Nome
Proporção
VanEck Biotech ETF
12.54%
ProShares Ultra Nasdaq Biotechnology
8.6%
Invesco Nasdaq Biotechnology ETF
8.54%
iShares Biotechnology ETF
7.24%
Simplify Health Care ETF
7.21%
Invesco Pharmaceuticals ETF
5.11%
Invesco Biotechnology & Genome ETF
5.08%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
4.62%
First Trust NASDAQ Pharmaceuticals ETF
4.12%
Tema Heart & Health ETF
3.95%
Ver Mais
VanEck Biotech ETF
Proporção12.54%
ProShares Ultra Nasdaq Biotechnology
Proporção8.6%
Invesco Nasdaq Biotechnology ETF
Proporção8.54%
iShares Biotechnology ETF
Proporção7.24%
Simplify Health Care ETF
Proporção7.21%
Invesco Pharmaceuticals ETF
Proporção5.11%
Invesco Biotechnology & Genome ETF
Proporção5.08%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
Proporção4.62%
First Trust NASDAQ Pharmaceuticals ETF
Proporção4.12%
Tema Heart & Health ETF
Proporção3.95%

Dividendo

Um total de 15.04B USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Feb 10, 2026
GILD.NB Interim Cash Dividend of gross USD 0.82 paid on Mar 30, 2026 going ex on Mar 13, 2026
Mar 13, 2026
Mar 30, 2026
Mar 13, 2026
Oct 30, 2025
GILD.NB Final Cash Dividend of gross USD 0.79 paid on Dec 30, 2025 going ex on Dec 15, 2025
Dec 15, 2025
Dec 30, 2025
Dec 15, 2025
Aug 07, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Sep 29, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Sep 29, 2025
Sep 15, 2025
Apr 24, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Jun 27, 2025 going ex on Jun 13, 2025
Jun 13, 2025
Jun 27, 2025
Jun 13, 2025
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Ver Mais

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI